Psoriasis

Por Griffiths, C E M, Baker, B S, Fry, L, Valdimarsson, H
Publicado em 1986

Defining cancer-risk, and assessing diagnostic usefulness of myositis serology, in dermatomyositis- Part 2

Por Madan, V, Chinoy, H, Griffiths, C E M, Cooper, R G
Publicado no Clin Exp Dermatol (2009)

IL-1β-induced Langerhans’ cell migration and TNF-α production in human skin: regulation by lactoferrin

Por CUMBERBATCH, M, BHUSHAN, M, DEARMAN, R J, KIMBER, I, GRIFFITHS, C E M
Publicado em 2003

Nonadherence to psoriasis medication as an outcome of limited coping resources and conflicting goals: findings from a qualitative interview study with people with psoriasis

Por Thorneloe, R.J., Bundy, C., Griffiths, C.E.M., Ashcroft, D.M., Cordingley, L.
Publicado no Br J Dermatol (2016)

No impairment of monocyte-derived Langerhans cell phenotype or function in early-onset psoriasis

Por Shaw, F L, Kimber, I, Begum, R, Cumberbatch, M, Dearman, R J, Griffiths, C E M
Publicado em 2012

Incidence, prevalence and mortality of patients with psoriasis: a U.K. population‐based cohort study

Por Springate, D.A., Parisi, R., Kontopantelis, E., Reeves, D., Griffiths, C.E.M., Ashcroft, D.M.
Publicado no Br J Dermatol (2016)

Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta‐analysis of randomized controlled trials

Por Rungapiromnan, W., Yiu, Z.Z.N., Warren, R.B., Griffiths, C.E.M., Ashcroft, D.M.
Publicado no Br J Dermatol (2017)

Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque‐type psoriasis...

Por Gerdes, S., Thaçi, D., Griffiths, C.E.M., Arenberger, P., Poetzl, J., Wuerth, G., Afonso, M., Woehling, H.
Publicado no J Eur Acad Dermatol Venereol (2017)

A novel mutation in IL36RN underpins childhood pustular dermatosis

Por Ellingford, J.M., Black, G.C.M., Clayton, T.H., Judge, M., Griffiths, C.E.M., Warren, R.B.
Publicado no J Eur Acad Dermatol Venereol (2015)

The global state of psoriasis disease epidemiology: a workshop report

Por Griffiths, C.E.M., van der Walt, J.M., Ashcroft, D.M., Flohr, C., Naldi, L., Nijsten, T., Augustin, M.
Publicado no Br J Dermatol (2017)

Effect of tofacitinib withdrawal and re‐treatment on patient‐reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis

Por Griffiths, C.E.M., Vender, R., Sofen, H., Kircik, L., Tan, H., Rottinghaus, S.T., Bachinsky, M., Mallbris, L., Mamolo, C.
Publicado no J Eur Acad Dermatol Venereol (2016)

Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial

Por Brooklyn, T N, Dunnill, M G S, Shetty, A, Bowden, J J, Williams, J D L, Griffiths, C E M, Forbes, A, Greenwood, R, Probert, C S
Publicado em 2006

‘New to me’: changing patient understanding of psoriasis and identifying mechanisms of change. The Pso Well(®) patient materials mixed‐methods feasibility study

Por Nelson, P.A., Kane, K., Pearce, C.J., Bundy, C., Chisholm, A., Hilton, R., Thorneloe, R., Young, H., Griffiths, C.E.M., Cordingley, L.
Publicado no Br J Dermatol (2017)

Investigating the role of the HLA-Cw*06 and HLA-DRB1 genes in susceptibility to psoriatic arthritis: comparison with psoriasis and undifferentiated inflammatory arthritis

Por Ho, P Y P C, Barton, A, Worthington, J, Plant, D, Griffiths, C E M, Young, H S, Bradburn, P, Thomson, W, Silman, A J, Bruce, I N
Publicado em 2008

Primary care‐based screening for cardiovascular risk factors in patients with psoriasis

Por Rutter, M.K., Kane, K., Lunt, M., Cordingley, L., Littlewood, A., Young, H.S., Chew‐Graham, C.A., Hilton, R., Symmons, D.P.M., Griffiths, C.E.M.
Publicado no Br J Dermatol (2016)

Association of Toll-like receptor 4 (TLR4) with chronic plaque type psoriasis and psoriatic arthritis

Por Smith, Rh. Ll., Hébert, H. L., Massey, J., Bowes, J., Marzo-Ortega, H., Ho, P., McHugh, N. J., Worthington, J., Barton, A., Griffiths, C. E. M., Warren, R. B.
Publicado no Arch Dermatol Res (2016)

Definition of treatment goals for moderate to severe psoriasis: a European consensus

Por Mrowietz, U., Kragballe, K., Reich, K., Spuls, P., Griffiths, C. E. M., Nast, A., Franke, J., Antoniou, C., Arenberger, P., Balieva, F., Bylaite, M., Correia, O., Daudén, E., Gisondi, P., Iversen, L., Kemény, L., Lahfa, M., Nijsten, T., Rantanen, T., Reich, A., Rosenbach, T., Segaert, S., Smith, C., Talme, T., Volc-Platzer, B., Yawalkar, N.
Publicado em 2010